Zaleplon in HIV Patients With Depression

Inclusion Criteria: 1. Male or female subjects aged 18-65 years with a diagnosis of asymptomatic seropositive HIV 2. Principal diagnosis of Major Depressive Disorder or Dysthymic Disorder in accordance with DSM-IV criteria, and receiving pharmacologic treatment. 3. Subject has obtained some subjective benefit from current antidepressant therapy and is agreeable to remain on the same medication for the course of this study 4. Current symptoms of insomnia as determined by a total score of at least 2 on items 4, 5, and 6 of the HAM-D, and specific complaint of sleep onset insomnia (sleep onset latency of at least 1 hour, 3 or more times per week)) 5. Free of sleep medication for at least 2 weeks prior to enrollment (we will not enroll any patients who might require weaning off of sedative hypnotic medications in order to be eligible for the study) 6. Ability to understand the requirements of the study and provide informed consent Exclusion Criteria: 1. Significant chronic, systemic illness or significant neurologic disorder, including traumatic brain injury 2. Clinically significant history of liver disease 3. Psychiatrically unstable patients in the clinical judgment of the investigator as indicated by current acute suicidality, current homicidal thoughts, or current psychosis 4. Lifetime history of schizophrenia, schizoaffective disorder, or any psychotic illness 5. History of substance abuse or dependence over the past 6 months 6. Currently taking medication to assist with sleep (e.g., Ambien/Zolpidem,Dalmane/Flurazepam, Doral/Quazepam, Halcion/Triazolam, Lunesta/Eszopiclone, Prosom/Estazolam, Restoril/Temazepam, Rozerem/Ramelteon, Sonata/Zaleplon, Melatonin, Unisom, Benadryl). 7. Pregnant